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letter to editorAberrant T-cell
antigen expression in
Jordanian children with
B lymphoblastic leukemia
To the Editor: Immunophenotypic
analysis is an important diagnostic
and prognostic component in the
management of acute lymphoblas-
tic leukemia (ALL). Currently, ﬂow
cytometry (FC) is considered the
standard test for phenotypic lineage
assignment in ALL. Aberrant mye-
loid antigen (M-Ag) expression in
B cell acute lymphoblastic leukemia
(B-ALL) is well documented, but
the aberrant expression of T cell
antigen (T-Ag) has not been
studied extensively. Reports from
North America and East Asia
estimate the prevalence of such
aberrant T-Ag expression to range
from 9% to 25%,1–4 with possible
adverse prognostic effect.
We retrospectively studied 94
Jordanian children (age < 19 years)
diagnosed with B-ALL, to assess
the prevalence and clinical signiﬁ-
cance of aberrant T-Ag expression.
Treatment protocol and response
assessment methods have pre-
viously been published.5 Fresh bone
marrow aspirate specimens were
processed for FC. Four-color FC
was performed according to stan-
dard procedures and utilizing com-
prehensive panels of monoclonal
antibodies. CD45+ and side-scat-
ter were used for gating strategy.
Aberrant phenotype expression
was dichotomized, and the thresh-
old was set at 20%. Cases expressing
the T-cell or myeloid speciﬁc anti-
gens (cytoplasmic CD3 or
myeloperoxidase) were excluded.
Ninety-four patients with med-
ian age of ﬁve years (range:
0–18 years) were analyzed. Based
on the National Cancer Institute
criteria, 62 patients (66%) were
stratiﬁed as standard risk and 32Hematol Oncol Stem Cell Ther 8(4) Fourth Quarter 20patients (34%) as high risk. After
a median follow-up of 37 months
(range: 7–54) the estimated four-
year, event-free survival and overall
survivals were 68% and 95%,
respectively. B-ALL showed
almost a consistent proﬁle that
was mostly positive for CD10,
CD19, TDT, and HLA-DR, and
negative for CD2, CD3, CD4,
CD5, CD7, and CD8.
Expression of T-Ag CD7 was
observed in one case only (1%),
and none of the other T-Ag mark-
ers (CD2, CD3, CD4, CD5,
CD8) were positive in the tested
patients. On the other hand, aber-
rant expression of M-Ag was com-
mon. The commonly expressed
M-Ags were: CD13 (26%),
CD33 (34%), and CD117 (9%).
Overall, T-Ag expression was
signiﬁcantly lower than all reports
from North America and East
Asia (P = 0.01, compared to refer-
ence number 1).
Our results differ from those of
Seegmiller et al. who reported
T-Ag expression in 18 of 200 cases
(9%), with CD4 being the most
common followed by CD7 and
CD5.1 In the report by Hussein
et al. 18 cases out of 134 (13.4%)
showed aberrant expression of
T-Ag.2 The most commonly
expressed T-Ags were CD2,
CD5, and CD7. Two reports from
East Asia by Shu and Chen
from China and Supriyadi et al.
from Indonesia reported similar
results.3,4 The interesting ﬁndings
of under-expression of T-Ag on
B-ALL in our cohort could be
multi-factorial: the possibility of
ethnicity as a factor in the immu-
nophenotypic proﬁle of leukemia
cells; the difference in the cutoff
point for positivity of CD markers
by FC; or the use of different anti-
body combinations. In addition to
the retrospective design of our15study, the other major limitation
is the lack of comprehensive stan-
dard panels in some of the cases,
especially for CD2 and CD3.
In conclusion, Jordanian chil-
dren with B-ALL have an almost
consistent phenotypic proﬁle,
which could help in the differentia-
tion of blasts from hematogones.
Our results showed that the occur-
rence of aberrant M-Ag in Jorda-
nian children with B-ALL was
high, but only one patient showed
aberrant expression of T-Ag. This
under-expression of T-Ag in our
cohort is not consistent with the
published literature from North
America and Asia. Further
investigation by Middle East
researchers into this phenomenon
and its possible link to ethnicity
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